In a nutshell This trial is aiming to examine the effectiveness and safety of atezolizumab (Tecentriq) and tiragolumab compared to durvalumab (Imfinzi) in stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed and has previously been treated with concurrent (at the same time) platinum-based chemoradiation therapy (CRT)....
Read MoreCurrent stage-Stage III Posts on Medivizor
Does chemotherapy after complete removal of rectal cancer improve outcomes?
In a nutshell This study investigated the differences in following the guidelines for advanced rectal cancer treatments. Researchers suggested chemotherapy after the complete removal of rectal cancer improves survival. Some background This year, an estimated 147,950 adults in the US will be diagnosed with colorectal cancer. Of these, 43,340 will be...
Read MoreLooking for patients with stage III non-small cell lung cancer to trial a treatment combination with radiotherapy
In a nutshell This study is looking to examine the effectiveness of durvalumab (Imfinzi) and consolidation stereotactic body radiation therapy (SBRT) after chemoradiation for locally advanced stage III non-small-cell lung cancer (NSCLC). The main outcomes to be measured are the occurrence of side effects and the survival without cancer...
Read MoreSearching for patients with advanced breast cancer to trial an experimental drug combination
In a nutshell This phase 2 trial will investigate the safety of experimental treatment zanidatamab (ZW25) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) in patients with advanced breast cancer (BC). The main outcomes evaluated will be the rate of side effects and survival without cancer worsening. This trial is...
Read MoreDo biological drugs work better alone or in combination with other drugs for patients with advanced non-small cell lung cancer who previously received treatment?
In a nutshell This study compared if anti-PD-1 biological drugs were more effective alone or when used with other drugs to treat patients with advanced non-small cell lung cancer who had previously received treatment. The results showed that the combination of anti-PD-1 and other drugs such as chemotherapy improved patients’ survival more than...
Read MoreIpilimumab vs high dose interferon for high risk melanoma
In a nutshell This study wanted to find out which was the better treatment for advanced melanoma that has been surgically treated, ipilimumab (Yervoy) or high dose interferon alfa (HDI). The study found that low dose ipilimumab resulted in better overall survival than HDI and high dose ipilimumab, but all of the treatments had...
Read MoreLooking for patients with advanced triple negative breast cancer to test an experimental drug with three functions
In a nutshell This trial is examining the safety and effectiveness of experimental drug mRNA-2752 in patients with advanced triple-negative breast cancer. The main outcome of the trial will be the number of side effects experienced by patients and response to treatment. This trial is recruiting in the United States and Israel. The details...
Read MoreLooking for postmenopausal women with advanced breast cancer to try a hormonal therapy
In a nutshell This study is looking for postmenopausal patients with advanced breast cancer with an ESR1 mutation to compare lasofoxifene (Fablyn) to fulvestrant (Faslodex). The main outcome measured in this trial will be the patient’s survival without tumor growth or spread. This trial is recruiting in multiple locations in the United...
Read MoreSearching for patients with advanced lung cancer to test an experimental drug
In a nutshell This phase 1/2 trial will investigate the safety and effectiveness of APL-101 in advanced non-small cell lung cancer (NSCLC). The main outcomes will be to determine the recommended phase 2 dose (RP2D) and the response rate (RR) in phase 2. This trial is recruiting at multiple locations across the US. The details...
Read MoreLooking for patients with advanced melanoma to test a combination of antibody and enzyme drugs
In a nutshell This trial is examining if adding antibody drug rituximab (Rituxan) and enzyme drug hyaluronidase human (Hycela) can increase the effectiveness of the standard treatment for melanoma. The main outcomes of this trial will be to examine the side effects experienced by patients and tumor response. This study is recruiting in...
Read MoreSearching for patients with advanced colorectal cancer to test a new combination therapy
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In many...
Read MoreSearching for patients with advanced triple-negative breast cancer to test a new combination treatment
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...
Read More